Hello,
According to the attached letter
It was written that "The definitions given for IFG or IGT in terms of the range of FPG were inconsistent across studies.".
In table 1, I knew that The World Health Organization (WHO, 1999) and the American Diabetes Association (ADA, 2003) utilise different cut-off values for IFG (WHO: 6.1–6.9 mmol/L; ADA: 5.6–6.9 mmol/L)
However, I can't understand completely why the authors of 3 RCTs used the cut-off 5.3 mmol/L. We contacted authors already but we don't think they would reply me because these papers were published before 2012.
Could you please explain why the cut-off was 5.3 mmol/L, not 5.6 mmol/L nor 6.1 mmol/L?
Thanks in advance.
Ngan
Broadly, I may think that changes in cut-off points for measurements in many diagnoses of (many diseases) result from improvements in understanding of the disease aetiology and associated pathophysiology. I'm not sure of the 3 RCTs that you have alluded to in your question, but most likely, the changes or adjustments in the cut-off points came in at different times (in years) after new studies came up and new results to inform new suggested cut-off points.
A good example of a disease that we have seen many versions of diagnosis and/or treatment or prevention or vaccination requirements is the Covid 19. Due to its new and constant being studied, over a few years (if not months) we have seen the WHO and many other regulatory bodies changing and adjusting strategies to its containment - why because new discoveries and a better understanding of it emerge. The same with the different cut-off points you have referred to in your quest.
Thanks.
- Badges
- Science topic
- Similar topics
- Biological Science
- Genetics
- Gene Expression